Patients with TET2 mutations tended to have positive B symptoms (P = 0.025), elevated LDH level (P = 0.037) and advanced disease (P = 0.001), while PTCL patients with TP53 mutations were more likely to presented with higher Ki-67 expression (P = 0.029). This evidence concerns the gene TP53 and mature T-cell and NK-cell non-Hodgkin lymphoma.